PNB Vesper is focused on developing cost-effective drugs for unmet medical needs. We have synthesized hundreds of molecules and systematically characterized them to select the lead molecules. The lead molecules have the potential to treat a variety of diseases including Covid 19, Inflammatory pain, Different kinds of Cancer, Inflammatory bowel disease (IBD), Neurological diseases such as Anxiety and Depression, Metabolic disorders, and others.
| Molecules | Molecular target | Therapeutic indication | Stage of development | |
|---|---|---|---|---|
| PNB-001 | CCK2 |
COVID 19 Inflammatory Bowel Disease
Inflammatory Pain |
Clinical Phase 3 (India) Clinical Phase 2 (India) |
View |
| PNB-028 | CCK3a or CCK-C isoform-selective antagonist |
Colon Cancer Pancreatic Cancer (Association with Tata Memorial Hospital – Mumbai) |
Clinical Phase 1/2 (India) |
View |
| PNB-081 | CCK1 or CCK-A antagonist |
Opioid Addiction Disorder (Association with NIH- USA) Pancreatitis |
Completed Preclinical studies Ready to start IND Regulatory studies |
View |
| PNB-101 | CCK-B gastrin antagonist |
Gastric cancer Small cell lung cancer |
Preclinical development |
View |
| PNB-291 | Pan-CCK blocker |
Brain cancer CCK cancers |
Completed Preclinical studies Ready to start IND Regulatory studies |
View |
| PNB-091 | CCK mixed antagonist |
Cocaine addiction Disorder (Association with NIH – USA) |
Completed Preclinical studies Ready to start IND Regulatory studies |
View |